

Product Data Sheet

Product Name: GZD-552

Cat. No.: GC81328

Chemical Properties

Cas. No.

Formula C₂₇H₃₀F₃N₅O₆

M.Wt 577.55


Solubility

Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

GZD-552 is a potent orally active FAK inhibitor with a human FAK IC₅₀ of 5.8 nM. GZD-552 suppresses FAK phosphorylation activation and downstream ERK signaling. GZD-552 induces apoptosis and G2/M cell cycle arrest, and exhibits antiproliferative activities in glioblastoma multiforme cells. GZD-552 exhibits antitumor efficacy in mice xenograft model. GZD-552 can be used for the research of glioblastoma multiforme [1].

In Vivo, GZD-552 (compound 16c) (10 and 20 mg/kg/day; i.g.; daily; 18 days) inhibits tumor growth in

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

mouse U87-MG xenograft model without detectable systemic toxicity^[1].

In Vitro, GZD-552 (compound 16c) potently and selectively inhibits the proliferation of U87-MG and U118-MG glioblastoma cells with IC₅₀ values of 6.6 nM and 4.3 nM, respectively, and shows limited activity against NCI-H1975 (IC₅₀ = 0.16 μM), MDA-MB-231 (IC₅₀ = 0.28 μM), and LO2 cells (IC₅₀ = 0.74 μM)^[1]. GZD-552 strongly and stably binds to FAK protein in U87-MG cells^[1]. GZD-552 (0.002-0.08 μM) suppresses FAK protein expression and activation, and downregulates downstream ERK phosphorylation in U87-MG cells in a concentration-dependent manner^[1]. GZD-552 (0.004-0.12 μM; 24 h) induces dose-dependent apoptosis and G2/M cell cycle arrest in U87-MG cells^[1].

References:

[1]. Xu Y, et al. Design, synthesis, and anti-glioblastoma multiforme evaluation of novel multikinase inhibitors via a cyclization strategy with potent FAK inhibition. Eur J Med Chem. 2026;312:118877.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA